These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32413420)

  • 21. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of CDK4/6 inhibitor for breast cancer.
    Iwata H
    Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Zangardi ML; Spring LM; Blouin GC; Bardia A
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
    El Rassy E; Bakouny Z; Assi T; Kattan J
    Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
    Costa R; Costa RB; Talamantes SM; Helenowski I; Peterson J; Kaplan J; Carneiro BA; Giles FJ; Gradishar WJ
    Breast; 2017 Oct; 35():1-7. PubMed ID: 28618307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
    Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Vidam G; Wang Y; Rodriguez Lorenc K; Miller M; Taran T; Jerusalem G
    J Clin Oncol; 2018 Aug; 36(24):2465-2472. PubMed ID: 29860922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer.
    Bozkaya Y; Ay B
    Breast J; 2020 Apr; 26(4):773-774. PubMed ID: 31486200
    [No Abstract]   [Full Text] [Related]  

  • 31. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
    Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
    Eiger D; Wagner M; Pondé NF; Nogueira MS; Buisseret L; de Azambuja E
    Acta Oncol; 2020 Jun; 59(6):723-725. PubMed ID: 32167397
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.
    Germa C; Miller M; Mukhopadhyay P; Hewes B; Caponigro G; Scherer SJ; Hirawat S
    Ann Oncol; 2017 Aug; 28(8):2021-2024. PubMed ID: 28838206
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.
    Duso BA; Trapani D; Viale G; Criscitiello C; D'Amico P; Belli C; Mazzarella L; Locatelli M; Minchella I; Curigliano G
    Expert Opin Pharmacother; 2018 Feb; 19(3):299-305. PubMed ID: 29355400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
    Coussy F; Deluche E; Pistilli B; Ladoire S; Ferrero JM; Cottu P
    Bull Cancer; 2021 Sep; 108(9):843-854. PubMed ID: 34154797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
    Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
    Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
    Im SA; Lu YS; Bardia A; Harbeck N; Colleoni M; Franke F; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva-Vazquez R; Jung KH; Chakravartty A; Hughes G; Gounaris I; Rodriguez-Lorenc K; Taran T; Hurvitz S; Tripathy D
    N Engl J Med; 2019 Jul; 381(4):307-316. PubMed ID: 31166679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ribociclib Causing Transient Glanzmann Thrombasthenia-like Picture: A Report of 4 Cases.
    Awidi AS; Bawa'neh HS; Al-Showbaki LN; Alqaisi HA; Awidi MA; Khalil LT; El Khatib OH; Mansour AT
    Clin Breast Cancer; 2019 Oct; 19(5):e593-e595. PubMed ID: 31311720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.